CN104740680A - 一种镁基生物材料组合物及其制备方法与应用 - Google Patents
一种镁基生物材料组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN104740680A CN104740680A CN201510080356.5A CN201510080356A CN104740680A CN 104740680 A CN104740680 A CN 104740680A CN 201510080356 A CN201510080356 A CN 201510080356A CN 104740680 A CN104740680 A CN 104740680A
- Authority
- CN
- China
- Prior art keywords
- parts
- hydroxyapatite
- magnesium oxide
- material composition
- magnesio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 239000012620 biological material Substances 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000011777 magnesium Substances 0.000 title abstract description 8
- 229910052749 magnesium Inorganic materials 0.000 title abstract 7
- 238000002360 preparation method Methods 0.000 title description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 92
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 76
- 239000007788 liquid Substances 0.000 claims abstract description 73
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 60
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 59
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 59
- 229930006000 Sucrose Natural products 0.000 claims abstract description 58
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 58
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims abstract description 47
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 47
- 239000000843 powder Substances 0.000 claims abstract description 45
- 239000002738 chelating agent Substances 0.000 claims abstract description 37
- 239000000463 material Substances 0.000 claims abstract description 29
- 239000007864 aqueous solution Substances 0.000 claims abstract description 22
- 239000004568 cement Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 15
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 12
- 238000007596 consolidation process Methods 0.000 claims description 70
- 239000005720 sucrose Substances 0.000 claims description 57
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 46
- 238000002156 mixing Methods 0.000 claims description 35
- 229910019142 PO4 Inorganic materials 0.000 claims description 24
- 239000010452 phosphate Substances 0.000 claims description 24
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 24
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 6
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 6
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 235000013681 dietary sucrose Nutrition 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 abstract 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 239000002002 slurry Substances 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 22
- 238000003756 stirring Methods 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 229910021645 metal ion Inorganic materials 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002798 polar solvent Substances 0.000 description 5
- 206010011732 Cyst Diseases 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 229940124280 l-arginine Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca+2].OP(O)(O)=O.OP(O)(O)=O YYRMJZQKEFZXMX-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002426 superphosphate Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000007712 rapid solidification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- MSXHSNHNTORCAW-GGLLEASOSA-M sodium;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O MSXHSNHNTORCAW-GGLLEASOSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
编号 | 组分加入顺序 | 细胞增殖率 |
实施例1 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 119.6% |
实施例2 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 98.2% |
实施例3 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 93.7% |
实施例4 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 93.3% |
实施例5 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 101.5% |
实施例6 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 91.4% |
实施例7 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 89.7% |
实施例8 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 95.7% |
实施例9 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 97.3% |
实施例10 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 87.5% |
实施例11 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 90.3% |
实施例12 | 氧化镁、磷酸二氢钾+固化液+蔗糖、羟基磷灰石、金属螯合剂 | 93.4% |
对比例1 | 氧化镁、磷酸二氢钾、蔗糖、羟基磷灰石、金属螯合剂+固化液 | 60.4% |
对比例2 | 氧化镁、磷酸二氢钾、羟基磷灰石、蔗糖+固化液(水) | 51.2% |
样本 | 平均记分 | 反应类型 |
极性溶剂浸提实施例1浆体 | 0 | 无 |
非极性溶剂浸提实施例1浆体 | 0.2 | 极轻微 |
极性溶剂浸提对比例2浆体 | 0.3 | 轻微 |
非极性溶剂浸提对比例2浆体 | 0.6 | 轻度 |
阳性对照 | 6 | 重度 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510080356.5A CN104740680B (zh) | 2015-02-13 | 2015-02-13 | 一种镁基生物材料组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510080356.5A CN104740680B (zh) | 2015-02-13 | 2015-02-13 | 一种镁基生物材料组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104740680A true CN104740680A (zh) | 2015-07-01 |
CN104740680B CN104740680B (zh) | 2017-01-25 |
Family
ID=53581289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510080356.5A Active CN104740680B (zh) | 2015-02-13 | 2015-02-13 | 一种镁基生物材料组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104740680B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105536046A (zh) * | 2016-02-26 | 2016-05-04 | 闫策 | 一种含双硫键的可注射骨水泥及制备方法 |
CN111888521A (zh) * | 2020-06-11 | 2020-11-06 | 上海蕴邦生物科技有限公司 | 骨修复材料及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006076426A2 (en) * | 2005-01-12 | 2006-07-20 | Lally Thomas J | Multi-purpose bio-material composition |
CN102274543A (zh) * | 2011-08-01 | 2011-12-14 | 天津美基生物医药科技有限公司 | 镁基骨填充粘合剂及其制备方法与应用 |
US20120100225A1 (en) * | 2010-10-25 | 2012-04-26 | Warsaw Orthopedic, Inc. | Osteoinductive bone graft injectable cement |
CN102515576A (zh) * | 2011-12-05 | 2012-06-27 | 苏州达普生物技术有限公司 | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 |
-
2015
- 2015-02-13 CN CN201510080356.5A patent/CN104740680B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006076426A2 (en) * | 2005-01-12 | 2006-07-20 | Lally Thomas J | Multi-purpose bio-material composition |
US20120100225A1 (en) * | 2010-10-25 | 2012-04-26 | Warsaw Orthopedic, Inc. | Osteoinductive bone graft injectable cement |
CN102274543A (zh) * | 2011-08-01 | 2011-12-14 | 天津美基生物医药科技有限公司 | 镁基骨填充粘合剂及其制备方法与应用 |
CN102515576A (zh) * | 2011-12-05 | 2012-06-27 | 苏州达普生物技术有限公司 | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 |
Non-Patent Citations (2)
Title |
---|
FAN SHIJIAN等: ""Experimental study of phosphate salts influencing properties of magnesium phosphate cement"", 《CONSTRUCTION AND BUILDING MATERIALS》 * |
李均明等: ""磷酸镁生物骨胶的制备与性能表征"", 《材料热处理学报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105536046A (zh) * | 2016-02-26 | 2016-05-04 | 闫策 | 一种含双硫键的可注射骨水泥及制备方法 |
CN105536046B (zh) * | 2016-02-26 | 2018-08-07 | 闫策 | 一种含双硫键的可注射骨水泥及制备方法 |
CN111888521A (zh) * | 2020-06-11 | 2020-11-06 | 上海蕴邦生物科技有限公司 | 骨修复材料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104740680B (zh) | 2017-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2407552C2 (ru) | Инъецируемый композитный материал, пригодный для использования в качестве заменителя костной ткани | |
TWI556842B (zh) | 包含鍶化合物之纖維蛋白組合物 | |
CN104147639B (zh) | 含锶可注射骨水泥及制备方法 | |
EP2851096B1 (en) | Composition for repairing cartilage tissue, method for producing same, and use thereof | |
CN104911427B (zh) | 一种Mg‑Ca‑Sr‑Zn系镁合金及其制备方法与应用 | |
CN102452831B (zh) | 骨水泥制剂以及由该骨水泥制剂制备的生物可再吸收的硬化骨水泥复合材料 | |
CN105457097A (zh) | 一种可注射矿化胶原骨修复材料及制备方法 | |
CN105251058B (zh) | 一种载药促骨生长注射型硫酸钙骨水泥的制备方法 | |
JP2001516264A (ja) | 抗生物質含有骨用セメントペースト | |
CN108658102B (zh) | 一种提高磷酸镁骨水泥生物相容性的氧化镁原料及其制备方法 | |
JP2019514651A (ja) | 変性骨を処置するための方法および組成物 | |
CN112023120A (zh) | 一种可注射预灌装骨修复颗粒及其制备方法和应用 | |
CN107233627B (zh) | 一种含魔芋葡甘聚糖的磷酸钙骨水泥及其制备方法和应用 | |
KR20130021385A (ko) | 콜라겐 하이드로겔 제조용 멀티 시린지 | |
CN104740680A (zh) | 一种镁基生物材料组合物及其制备方法与应用 | |
CN109276754A (zh) | 一种促生长的可注射骨水泥及其制备方法 | |
CN102488921B (zh) | 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 | |
RU2504405C1 (ru) | Остеогенный биорезорбируемый материал для замещения костных дефектов и способ его получения | |
CN106310357B (zh) | 一种骨填充黏合剂及其制备方法及应用 | |
WO2015133963A1 (en) | Compound for stimulating bone formation | |
RU2609835C1 (ru) | Кальций-фосфатный цемент для регенерации костной ткани (варианты) | |
CN109331226A (zh) | 一种改性矿化胶原人工骨材料及其制备方法和应用 | |
CN115554468B (zh) | 含生物活性玻璃的骨水泥及其制备方法和应用 | |
CN103656759A (zh) | 复合性骨水泥 | |
JP2015514535A5 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210105 Address after: 226100 B6 / F, No.100 Dongtinghu Road, Linjiang Town, Haimen City, Nantong City, Jiangsu Province Patentee after: Jiangsu Jingze Biomedical Co.,Ltd. Patentee after: CHINA WEST NORMAL University Patentee after: Chengdu Jingze biopharmaceutical Co.,Ltd. Address before: 215421 workshop 4, Xiangtang property, Zhenhui Road, Guizhuang District, Shaxi Town, Taicang City, Suzhou City, Jiangsu Province Patentee before: SUZHOU JINGZHUO BIOTECHNOLOGY Co.,Ltd. Patentee before: CHINA WEST NORMAL University Patentee before: CHENGDU DAPU MEDICAL DEVICES Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 230088 China (Anhui) pilot Free Trade Zone, Hefei, Anhui Province a11-1, 13 / F, block a, building J1, phase II, innovation industrial park, No. 2800, innovation Avenue, high tech Zone, Hefei Patentee after: Jingze biomedical (Hefei) Co.,Ltd. Patentee after: CHINA WEST NORMAL University Patentee after: Chengdu Jingze biopharmaceutical Co.,Ltd. Address before: 226100 B6 / F, No.100 Dongtinghu Road, Linjiang Town, Haimen City, Nantong City, Jiangsu Province Patentee before: Jiangsu Jingze Biomedical Co.,Ltd. Patentee before: CHINA WEST NORMAL University Patentee before: Chengdu Jingze biopharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220727 Address after: 230000 a11-1, 13 / F, block a, building J1, phase II, innovation industrial park, 2800 innovation Avenue, Hefei, Anhui Patentee after: Jingze biomedical (Hefei) Co.,Ltd. Patentee after: Chengdu Jingze biopharmaceutical Co.,Ltd. Address before: 230088 China (Anhui) pilot Free Trade Zone, Hefei, Anhui Province a11-1, 13 / F, block a, building J1, phase II, innovation industrial park, No. 2800, innovation Avenue, high tech Zone, Hefei Patentee before: Jingze biomedical (Hefei) Co.,Ltd. Patentee before: CHINA WEST NORMAL University Patentee before: Chengdu Jingze biopharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: A11-1, 13/F, Block A, Building J1, Phase II, Innovation Industrial Park, No. 2800, Innovation Avenue, High-tech Zone, Hefei, Anhui Province, 230088 Patentee after: Jingze Biomedical (Hefei) Co.,Ltd. Patentee after: Chengdu Jingze biopharmaceutical Co.,Ltd. Address before: 230000 a11-1, 13 / F, block a, building J1, phase II, innovation industrial park, 2800 innovation Avenue, Hefei, Anhui Patentee before: Jingze biomedical (Hefei) Co.,Ltd. Patentee before: Chengdu Jingze biopharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address |